Ibrutinib in B-cell lymphoma: single fighter might be enough?

Xue, Chao; Wang, Xin; Zhang, Lingyan; Qu, Qingyuan; Zhang, Qian; Jiang, Yujie

doi:10.1186/s12935-020-01518-y

Cited by 19 publications

(18 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ibrutinib is a first‐generation agent that inhibits BTK and is used primarily for CLL and small lymphocytic lymphoma (SLL). However, there is emerging evidence that it can also be used to manage other types of hematological malignancies 39 . We identified six case reports TLS while patients were treated with single‐agent ibrutinib for mantle cell lymphoma (MCL) ( N = 2) and CLL/SCLL ( N = 4) (Table 2).…”

Section: Resultsmentioning

confidence: 99%

“…However, there is emerging evidence that it can also be used to manage other types of hematological malignancies. 39 We identified six case reports TLS while patients were treated with single-agent ibrutinib for mantle cell lymphoma (MCL) (N = 2) and CLL/SCLL (N = 4) (Table 2). [40][41][42][43][44] The mean age was 69 years and five were male.…”

Section: Ibrutinibmentioning

confidence: 99%

See 1 more Smart Citation

Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review

Salter

Burns

Fuller

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Background Effective treatments for hematologic malignancies include therapies that target tyrosine kinase (TK) signaling pathways. Tumor lysis syndrome (TLS) is an oncologic emergency that can occur due to rapid turnover following the initiation of treatments for hematologic malignancy. The incidence of TLS is under‐reported and it is unclear as to whether TK inhibitors (TKIs) are associated with TLS. Objective To conduct a systematic review to determine the incidence of TLS with TKIs. Methods A search was performed using EMBASE, MEDLINE, and Web of Science electronic databases, as well as a manual search of the American Society of Hematology and American Society of Clinical Oncology abstract databases. Keywords included: “tumor lysis syndrome,” “tyrosine kinase inhibitors,” “lymphoma,” and “leukemia.” Results We identified a total of 57 publications that commented on the incidence of TLS with TKIs for hematologic malignancy. Thirty‐nine of those publications reported TLS as an adverse event. TLS was described as an adverse event among essentially all the subclasses of TKIs that are used to manage hematologic malignancies. Conclusion The overall number of articles commenting on TLS as an adverse event is sparse and there needs to be more transparency regarding the incidence of TLS when employing newer targeted therapies. Physicians should consider the risk of TLS on an individual basis and the added risk of TLS when using TKIs to treat hematologic malignancy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Ibrutinibmentioning

confidence: 99%

Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review

Salter

Burns

Fuller

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…NFAT : nuclear factor of activated T-cells. Created with based on information in [ 37 , 38 , 50 , 51 ].…”

Section: Figurementioning

confidence: 99%

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review

Sochacka-Ćwikła

Mączyński

Regiec

2021

Cancers

View full text Add to dashboard Cite

Hematological malignancies, also referred to as blood cancers, are a group of diseases involving abnormal cell growth and persisting in the blood, lymph nodes, or bone marrow. The development of new targeted therapies including small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody-drug conjugates, recombinant immunotoxins, and, finally, Chimeric Antigen Receptor T (CAR-T) cells has improved the clinical outcomes for blood cancers. In this review, we summarized 52 drugs that were divided into small molecule and macromolecule agents, approved by the Food and Drug Administration (FDA) in the period between 2011 and 2021 for the treatment of hematological malignancies. Forty of them have also been approved by the European Medicines Agency (EMA). We analyzed the FDA-approved drugs by investigating both their structures and mechanisms of action. It should be emphasized that the number of targeted drugs was significantly higher (46 drugs) than chemotherapy agents (6 drugs). We highlight recent advances in the design of drugs that are used to treat hematological malignancies, which make them more effective and less toxic.

show abstract

“…The first paradigm of therapeutic benefit targeting BTK was the rapid approval of ibrutinib by the US Food and Drug Administration (FDA) as a therapeutic option for chronic lymphocytic lymphoma/small lymphocytic lymphoma (CLL/SLL) and MCL (mantle cell lymphoma) in 2014 and 2013, respectively. It was subsequently approved as monotherapy in patients with lymphoplasmacytic lymphoma (LPL)/ WM (Waldenstrom's macroglobulinemia) and marginal zone lymphoma (MZL) in 2015 and 2017, respectively ( 10 ). Its safety profile has been a concern due to extended off-target kinase inhibition including Tec kinases, epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK) ( 11 ).…”

Section: B—cell Malignancies and Btk Inhibitionmentioning

confidence: 99%

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus

Patsatsi

Murrell

2021

Front. Med.

View full text Add to dashboard Cite

Bruton Tyrosine Kinase (BTK) has a key role in multiple pathways involved in inflammation and autoimmunity. Therefore, BTK has become a new therapeutic target for a group of hematologic and autoimmune disorders. The pharmaceutical industry has invested in the clinical development of BTK inhibitors during the last decade. Ibrutinib, for example, which was the first BTK inhibitor to be used in clinical trials, has two approved indications, mantle cell lymphoma and chronic lymphocytic leukemia, and remains under evaluation for additional indications. Rillzabrutinib (PRN1008) is a new, highly potent and selective inhibitor of BTK. Early studies performed in canine pemphigus demonstrated effectiveness. A proof-of-concept, multicenter, phase 2 trial has recently showed the efficacy and safety of oral rilzabrutinib in pemphigus vulgaris. In this mini review, we present evidence regarding the mechanisms affected by BTK inhibition and the concept of BTK inhibition as an emerging new treatment in pemphigus.

show abstract

Ibrutinib in B-cell lymphoma: single fighter might be enough?

Cited by 19 publications

References 62 publications

Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review

Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus

Contact Info

Product

Resources

About